Ocular manifestations of GVHD include keratoconjunctivitis sicca, cicatricial lagophthalmos, sterile conjunctivitis, persistent corneal epithelial defects, corneal ulcers and corneal melting. Conventional initial therapy such as lubrication and topical steroids is directed to treat decreased tear production and ocular surface abnormalities. The purpose of this study was to illustrate the possible benefit of topical cyclosporin A 1% (CsA) as an adjunct in managing ocular surface abnormalities in five cases of GVHD refractory to conventional therapy. Five clinical case reports of chronic GVHD patients in whom conventional therapy was inadequate to stop the progression from its initial presentation are described. Patient presentation varied in severity on a spectrum of mild to moderate diffuse punctate epithelial erosions to sterile necrotizing corneal melts. Although systemic therapy for GVHD consisting of systemic immunosuppressants (ie cyclosporin A and corticosteroids) was given to these patients, this therapy was insufficient in managing the ocular manifestations of the disease. Topical CsA was added to the treatment regimen and the progression of the ocular disease was recorded. The addition of topical CsA 1% probably helped in controlling the epithelial keratitis and melting process in our reported cases and we conclude that topical CsA may be an appropriate modality in managing ocular surface abnormalities in patients with ocular GVHD after conventional treatments have been tried. However, a further randomized clinical prospective study is needed to evaluate the efficacy of topical CsA in managing these problems in GVHD patients.
from 30 to 50%. [3] [4] [5] The acute form of GVHD is characterized by hepatic dysfunction and cutaneous changes. 3, 6 Manifestations of the chronic form include skin lesions, oral and esophageal mucositis, pulmonary insufficiency, chronic liver disease and ocular disease. 3, 4, 7, 8 Ocular manifestations were reported in 45 9 to 60% 10 of patients with GVHD. Manifestations include keratoconjunctivitis sicca, non-infectious conjunctivitis, punctate keratitis, corneal epithelial erosions, sterile corneal ulcers, corneal perforation, uveitis and microangiopathy of the retina described as cotton wool spots, retinal hemorrhages, edema of the optic disk and retinal lipoid deposits. [9] [10] [11] [12] [13] Ocular involvement after BMT has been described by Gratwohl et al 8 and Lawley 11 in 1977 as a Sjogren-like syndrome in cGVHD.
Dry eyes developed in 76% of aGVHD patients 12 and between 62.5% 14 and 81.8% 14 of cGVHD patients. Clinical tear function testing disclosed a strong correlation between the occurrence of aGVHD and a rapid decrease in tear secretion. This secondary Sicca does not respond well to the treatment of acute or chronic GVHD. 9 Patients can present with abnormal tear function tests and conjunctival histology changes without any eye symptoms, suggesting that the ocular change may be the only expression of subclinical GVHD. 15 The pathogenesis of ocular changes after BMT is still controversial. Secondary keratoconjunctivitis sicca may occur as a result of the pre-transplant regimen, which may include total body irradiation (TBI) and/or chemotherapy, or as an immune process after transplantation with or without TBI. Severe ocular manifestations such as pseudomembranous conjunctivitis, corneal epithelial defects, and corneal melting are associated with severe systemic cGVHD and poorer survival. 13 The clinical management of ocular surface problems from GVHD usually begins with lubricants, progressing to punctal occlusion, eye patching, and eventually tarsorrhaphy and conjunctival flap. 10, 16 In severe cases of GVHD, the conjunctival and corneal epithelial defect progress and symblepharon and corneal perforation occur. Topical steroids have been found to have very little beneficial effect for these patients.
9,13

Patients and methods
We followed five patients with severe ocular GVHD who did not responded to conventional therapy. These five patients were referred from the MD Anderson Cancer Center to the ophthalmology department for evaluation once they had been diagnosed with systemic GVHD based on skin biopsy or elevated liver enzymes. After the diagnosis for systemic GVHD had been made the patients were started with systemic cyclosporin A and systemic prednisone. Topical cyclosporin A 1% was added in a dose of one drop six to eight times per day for a period of 6 weeks after we received the patient and after they had undergone conventional therapy with topic steroids and lubricants. The clinical responses were recorded and are reported as follows.
Case 1 (LG)
A 48-year-old male with CML underwent allogeneic BMT in January 1995. Six months post BMT he complained of progressive blurred vision with mucous discharge in both eyes. The patient had no other clinical manifestations of systemic GVHD except for elevated liver enzymes. The visual acuity was 20/20 OU. His basal tear function was measured to be 4 mm in both eyes. Slit lamp examination revealed blepharitis, chemosis, conjunctival scarring, pseudomembranous conjunctivitis and palpebral conjunctival sloughing in both eyes. He was treated with topical steroid/antibiotic combination for 3 weeks without improvement. Topical CsA 1% was initiated at a frequency of six times a day. After 2 weeks of treatment with CsA, the patient's symptoms decreased and conjunctival reactions became inactive. A palpebral conjunctival scar developed in the upper tarsus. At the same time, the patient developed skin rashes and had elevated liver function tests. He was diagnosed with systemic cGVHD and systemic immunosuppressive drugs were started. The topical CsA was gradually tapered and then discontinued after 6 weeks. Two months after the active stage, the patient had chronic blepharitis and severe dry eyes with 0 mm of basal tear, conjunctival scar and positive Rose Bengal staining of the interpalpebral region of both eyes.
Case 2 (RF)
A 44-year-old female with AML underwent allogeneic BMT in March 1995. Six months after BMT, she developed cGVHD with abnormal liver function tests, skin rashes, oral ulcers and eye pain. Systemic immunosuppressive drugs were started. Initial eye examination showed a visual acuity of 20/40 OD and 20/30 OS, basal tear secretion was 4 mm OU. Slit lamp examination revealed slightly injected conjunctiva and a clear cornea OU. One week later, her visual acuity decreased to 20/100 OD and 20/50 OS with bilateral swollen eyelids, conjunctival injection, chemosis and pseudomembrane formation, punctate epithelial erosion OS and a 40% corneal epithelial defect OD. Despite lubrication and eye patching, the abrasion progressed to 80% and the patient was referred for further treatment evaluation. Topical CsA 1% and prednisolone 1 % at a frequency of eight times per day were started. After 1 week of treatment the eyelid swelling, conjunctival reaction, pseudomembranes and corneal defects were markedly decreased. A basal tear secretion test was 0 mm OU. Punctal occlusion was carried out and topical eye drops were slowly tapered over 6 weeks. Her vision improved to 20/20 OU with significantly decreased inflammation and resolution of the epithelial defects. The patient had irregular eyelid margins and scarring of the upper and lower fornices. Rose Bengal staining was positive for both eyelid margins, the interpalpebral conjunctival, the upper and lower bulbar conjunctival as well as the upper and lower one third of the cornea. At this convalescent stage the central cornea seem to be the least affected area in the eyes.
Case 3 (SN)
A 39-year-old male underwent allogeneic BMT for recurrent lymphoma in July 1995. Four months after BMT, he complained of dryness, irritation and photophobia and developed skin and oral manifestations of cGVHD. His vision was 20/30 with chemosis and punctate epithelial erosions in the central area of both cornea which did not resolve with lubrications. Topical steroid was added four times a day for 1 week. Examination on referral revealed irregular eyelid margins with obstructed meibomian gland openings, conjunctival injection and punctate staining of the cornea. There were multiple yellowish giant papillaelike conjunctival nodules at the lower tarsus and fornix. Cultures from both eyes were negative. The basal tear test was measured to be 3 mm OD and 4 mm OS. Topical CsA 1% was added at a frequency of six times a day. Conjunctival injection decreased and a scar developed at the upper tarsi and lower fornices. Rose Bengal staining pattern changed from central corneal staining to inferior and superior staining with dense staining at the eyelid margins, tarsi, and inferior and superior limbal conjunctiva. His repeated Schirmer basal tear test was 0 mm and the lower punctual were occluded.
Case 4 (FK)
A 39-year-old Middle Eastern female with underlying CML underwent allogeneic BMT with TBI in August 1993. After 6 months post BMT she developed severe cGVHD involving the skin, oral and genital mucosa, liver and eyes. Despite systemic immunosuppressive treatment, she developed bilateral corneal perforation which was treated with corneal glue, topical antibiotics and topical steroids. She was referred for further treatment. Initial examination revealed visual acuity of counting fingers at 3 feet OU and centrally perforated corneas with intact glue, and cataracts. We performed a penetrating keratoplasty, cataract extraction, intraocular lens implantation with tarsorrhaphy in her left eye. A regimen of topical steroids, CsA 1%, lubricants, and antibiotics were prescribed. A corneal epithelial defect developed on the graft after the tarsorrhaphy which was partially opened and the tarsorrhaphy was repeated and the defect improved. The same procedure was then carried out on the right eye 1 month later. After a partial release of the tarsorrhaphy, a corneal epithelial defect developed in the left eye and topical steroids were added without any improvement. However, the defect regressed with the addition of CsA 1% six times a day for a week. The patient had severe dry eyes with a Schirmer basal tear test of 0 mm O.U. Punctal occlusion was performed and copious lubrication was prescribed. Both corneas remained with punctate epithelial staining in the exposed areas and the eyelid margins were irregular with inspisated meibomian orifices. Her best corrected visual acuity was 20/70 OD and 20/200 OS.
Case 5 (GW)
A 43-year-old male underwent allogeneic BMT for AML in October 1992. He developed severe dry eyes with a Schirmer basal tear test of 0 mm 6 months after BMT. Best corrected visual acuity was 20/50 OD and 20/40 OS. His examination showed irregular eyelid margins and punctate epithelial erosions in both eyes. Punctal occlusion was performed and artificial tears were prescribed. He developed a rheumatoid-like perforation of his right cornea that was successfully glued. A combined penetrating keratoplasty with cataract extraction and intraocular lens implantation with tarsorrhaphy was performed in his right eye after initial treatment with topical and systemic steroids. Six months after the surgery, the right eye developed stromal edema along the superonasal graft-host junction that progressed to a corneal epithelial defect. Topical steroid dosage was increased, but with minimal response. Topical CsA 1% was then added eight times a day. The epithelial defect, infiltration area and stromal edema slowly improved with this treatment. However, the patient still exhibited residual stromal edema and a slightly hazy cornea secondary to the scar. He had significant Rose Bengal staining along the eyelid margins, the interpalpebral conjunctiva, the upper and lower tarsi and the superior and inferior corneoscleral junction. The patient has stabilized currently with a visual acuity of 20/80 OD and 20/40 OS.
Discussion
GVHD is an immunological reaction initiated by donor T lymphocytes which acts against host tissues, including the eyes. Previous skin biopsy studies have revealed predominantly CD8
+ cells in cGVHD. [17] [18] [19] [20] [21] Electron microscopy has demonstrated intimate contact between CD8 + cells and degenerated keratinocytes suggesting that cytotoxic cells may play a role in the cytotoxic process of the tissue. 20, 21 Ocular symptoms may be the first presentation of GVHD and they may be seen in the absence of systemic manifestations of GVHD. These symptoms may be easily missed or attributed to simple dry eyes in these patients and the ophthalmologist and oncologist need to be aware of the possibility of ocular GVHD in patients who have undergone an allogeneic BMT. The natural course of ocular GVHD may be categorized into four stages. The initial subclinical stage can manifest as tearing, mild nonspecific discomfort, and photophobia. The eyes look slightly infected, may have mild chemosis and may or may not have positive Rose Bengal staining. The basal tear test can be normal. This stage can last for a few days to as long as 1 month before patients start to have other systemic manifestations of GVHD or progress to a more severe form of ocular GVHD. In the active stage of ocular GVHD, patients usually have other systemic manifestations of GVHD. The eye findings range from mucopurulent conjunctivitis and pseudomembranous conjunctivitis to punctate keratitis and corneal abrasion. After this stage, the patients either enter the convalescent stage of the disease when the inflammatory process stops or proceed to a necrotizing stage in which the cornea starts to melt and may eventually perforate. In our clinical experience, patients progressing to this necrotizing stage with loss of corneal epithelium and corneal melting are usually associated with a grave systemic prognosis. The convalescent stage is characterized by secondary sicca. Slit lamp examination reveals irregular eyelid margins with obstructed meibomian gland orifices, tarsal and forniceal scarring and punctate corneal epitheliopathy. Besides the dry eye pattern of Rose Bengal staining, the eyes are heavily stained at the posterior lamellae of the eyelid margins and the superior and inferior limbus.
The pathogenesis of ocular GVHD is not completely understood. As previously described, CD4 is the predominant cell type expressed in the conjunctiva of the acute GVHD. 13, 17 We postulate that the apparent benefit of topical CsA 1% seen in our patients may result from the pharmacological action of cyclosporin A as a potent immunosuppressor, especially for T helper cells. 22, 23 Previous studies have shown that topical CsA 1-2% can be used safely and effectively in human eyes status post penetrating keratoplasty for allograft rejection, vernal keratoconjunctivitis, keratoconjunctivitis sicca, immune-mediated keratitis, necrotizing scleritis and stromal herpetic keratitis. [24] [25] [26] [27] [28] [29] Considerable evidence exists that topical cyclosporin A reduces the lacrimal gland infiltrate and improves tear production in keratoconjunctivitis sicca dogs, [30] [31] [32] [33] and a few clinical studies indicate that systemic or topical cyclosporine improves some objective or subjective signs of keratoconjunctivitis sicca in patients with or without Sjogren's syndrome. [34] [35] [36] Therefore, it appears that cyclosporin A may target the tear deficient aspect of dry eye by modulating the immune reactivity and inflammatory processes of both senescence-related dry eye as well as the dry eye condition associated with Sjogren's syndrome.
Diverse studies have been conducted measuring the tissue levels of cyclosporine in tears, conjunctiva, aqueous humor and serum following topical and systemic administration of cyclosporine A in animals and humans. [37] [38] [39] [40] [41] [42] Following systemic application the concentration of cyclosporin A in aqueous humor is reported to be higher compared with topical use. 41 The level of cyclosporin A in the conjunctiva was significantly higher after topical application compared with systemic. 42 The systemic absorption of topical cyclosporin A is minimal, being the average maximum whole blood concentration (Cmax) of less then 0.2 ng/ml. 43 Therefore topical ocular application of cyclosporin A, which gives greater concentration in conjunctiva than systemic and reduces or eliminates the drug's systemic sideeffects, can be used to induce local immunosuppressive activity, particularly in the treatment of superficial immunological diseases. We find that topical CsA 1%, given six to eight times per day during the active or necrotizing stage of the disease, may help promote the healing process and decrease the immunology activity from the donor lymphocytes which activate the immune cascade. However, in the convalescent stage of the disease, topical CsA 1% seems to have no beneficial effect for the patient. The ocular surface changes seen at this stage are likely the result of the pre-viously active immunological process. As the result of this inflammation, the meibomian glands located at the lid margins, the surface epithelium of the conjunctiva and cornea, the goblets cells, and the lacrimal glands are destroyed, leading to severe ocular surface problems. Punctal occlusion with frequent use of preservative-free lubrication is the initial approach with bandage contact lenses and nonpreserved topical steroids being additional options for these patients.
We conclude that the use of topical CsA in the early period of ocular GVHD can minimize the immune destruction responsible for the development of keratitis sicca. The local inhibitory effect of CsA on T lymphocytes and cytokine production may decrease the tissue destruction and allow wound healing processes to occur. However, future prospective controlled studies are needed to validate further the effect of topical cyclosporin A in ocular GVHD.
